Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Vaccinations01:51

Vaccinations

Overview
Atomic Structure01:33

Atomic Structure

Overview
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced B cell priming induces broadly neutralizing HIV-1 apex antibodies.

Nature·2026
Same author

Neutralizing antibodies elicited in nonhuman primates by an enterovirus D68 virus-like particle vaccine target receptor binding sites.

Science translational medicine·2026
Same author

A functional investigation of antibody Fc-FcRn variant binding guided by <i>in silico</i> free energy perturbation methods.

bioRxiv : the preprint server for biology·2026
Same author

Deep mining of the human antibody repertoire identifies frequent and genetically diverse CDRH3 topologies targetable by vaccination.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Germline-targeting HIV immunogen induces cross-neutralizing antibodies in outbred macaques.

Immunity·2026
Same author

Early clonal dominance at priming sets the trajectory for broad HIV serum neutralization.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: May 31, 2026

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

Vaccine design reaches the atomic level.

Peter D Kwong1, Lawrence Shapiro

  • 1Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. pdkwong@nih.gov

Science Translational Medicine
|July 15, 2011
PubMed
Summary
This summary is machine-generated.

Developing broadly effective vaccines against diverse pathogens like meningococcus B is challenging. Structure-based design created a single immunogen protecting against over 300 variants, showcasing a powerful approach for future vaccine development.

More Related Videos

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform
06:27

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Published on: October 20, 2020

Related Experiment Videos

Last Updated: May 31, 2026

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform
06:27

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Published on: October 20, 2020

Area of Science:

  • Immunology
  • Structural Biology
  • Vaccinology

Background:

  • Genetic diversity in pathogens like meningococcus B complicates the development of vaccines with broad efficacy.
  • Existing vaccine strategies often struggle to provide protection against the wide array of natural variants of a single pathogen.

Purpose of the Study:

  • To design a single immunogen capable of eliciting protective immunity against a large number of meningococcus B variants.
  • To demonstrate the potential of structure-based vaccine design in overcoming pathogen genetic diversity.

Main Methods:

  • Integration of atomic-level structural data with genomic information.
  • Application of classical vaccinology principles.
  • Design and testing of a novel immunogen.

Main Results:

  • A single immunogen was successfully designed.
  • This immunogen demonstrated the ability to elicit protective immunity against over 300 natural variants of meningococcus B.
  • The study highlights the efficacy of structure-based design for broad pathogen coverage.

Conclusions:

  • Structure-based vaccine design is a powerful strategy for creating immunogens against genetically diverse pathogens.
  • This approach can overcome limitations of traditional vaccinology in addressing pathogen variability.
  • The developed immunogen offers a promising avenue for a broadly protective meningococcus B vaccine.